抗血管内皮生长因子治疗与脉络膜骨瘤相关的脉络膜新生血管:一个基于案例研究的回顾。

IF 0.9 Q3 OPHTHALMOLOGY
Journal of Current Ophthalmology Pub Date : 2025-09-18 eCollection Date: 2024-10-01 DOI:10.4103/joco.joco_74_24
Sahba Fekri, Amir Hossein Farahi, Maryam Zamani
{"title":"抗血管内皮生长因子治疗与脉络膜骨瘤相关的脉络膜新生血管:一个基于案例研究的回顾。","authors":"Sahba Fekri, Amir Hossein Farahi, Maryam Zamani","doi":"10.4103/joco.joco_74_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.</p><p><strong>Conclusion: </strong>Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"462-467"},"PeriodicalIF":0.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487803/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.\",\"authors\":\"Sahba Fekri, Amir Hossein Farahi, Maryam Zamani\",\"doi\":\"10.4103/joco.joco_74_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.</p><p><strong>Conclusion: </strong>Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.</p>\",\"PeriodicalId\":15423,\"journal\":{\"name\":\"Journal of Current Ophthalmology\",\"volume\":\"36 4\",\"pages\":\"462-467\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487803/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Current Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/joco.joco_74_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joco.joco_74_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:报道1例13岁脉络膜骨瘤合并脉络膜新生血管(CNV)患者应用抗血管内皮生长因子(anti-VEGF)药物治疗,并结合相关文献回顾这些药物的疗效。方法:病例报告。结果:1例13岁女孩右眼突发性视力丧失。眼科检查发现大脉络膜骨瘤并发视网膜下及视网膜下色素上皮(rpe)出血,提示CNV。给予玻璃体内贝伐单抗注射,导致视力和视网膜下和rpe下出血的分辨率显著改善。随访显示,随着CNV的消退,无需进一步注射。文献回顾发现25例CNV合并脉络膜骨瘤,贝伐单抗是最常用的抗vegf药物。通常需要多次注射,尽管在某些情况下单次注射也证明有效。大多数患者在治疗后视力有所改善。结论:抗vegf药物,如贝伐单抗,似乎是脉络膜骨瘤继发性CNV的一种有希望的治疗选择,可能通过有限的注射来保护和改善视力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.

Purpose: To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.

Methods: Case report.

Results: A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.

Conclusion: Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
6.70%
发文量
45
审稿时长
8 weeks
期刊介绍: Peer Review under the responsibility of Iranian Society of Ophthalmology Journal of Current Ophthalmology, the official publication of the Iranian Society of Ophthalmology, is a peer-reviewed, open-access, scientific journal that welcomes high quality original articles related to vision science and all fields of ophthalmology. Journal of Current Ophthalmology is the continuum of Iranian Journal of Ophthalmology published since 1969.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信